Phylogica Expands Collaboration with Janssen for peptide-drug conjugates

PERTH, AUSTRALIA: 01 July 2013 – Phylogica Ltd (ASX: PYC, XETRA: PH7), a leading Australian peptide drug discovery company, announced today the expansion of its collaboration with Janssen Biotech, Inc. (“Janssen”) to discover, develop and commercialise new classes of peptide drug conjugates derived from Phylogica’s Phylomer drug discovery platform. Phylogica has received an undisclosed payment for funding additional research associated with the expansion of the collaboration.

The agreement with Janssen was originally executed in December 2011. This expansion of the collaboration follows the successful identification of Phylomers that specifically target the tissue-type of interest and internalise a payload within the cell. This screening phase was conducted using Phylogica’s second-generation Phylomer libraries and newly developed technology to detect Phylomer conjugates that not only penetrate cells but, importantly, also deliver their payload functionally within the cell (known as ‘endosomal escape’). Phylogica has recently filed a patent application on this platform enhancement.

To read the full ASX announcement, please download the document below.